Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Cash (2022 - 2025)

Historic Change in Cash for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$11.8 million.

  • Corvus Pharmaceuticals' Change in Cash fell 1636.65% to -$11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 8824.64%. This contributed to the annual value of -$3.9 million for FY2024, which is 61985.16% down from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Change in Cash is -$11.8 million, which was down 1636.65% from $9.7 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Change in Cash high stood at $12.4 million for Q3 2023, and its period low was -$32.0 million during Q1 2022.
  • Moreover, its 4-year median value for Change in Cash was -$3.7 million (2025), whereas its average is -$4.0 million.
  • Over the last 5 years, Corvus Pharmaceuticals' Change in Cash had its largest YoY gain of 46999.0% in 2024, and its largest YoY loss of 18163.41% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Change in Cash (Quarter) stood at -$11.4 million in 2022, then skyrocketed by 34.51% to -$7.5 million in 2023, then skyrocketed by 154.24% to $4.1 million in 2024, then tumbled by 391.23% to -$11.8 million in 2025.
  • Its Change in Cash stands at -$11.8 million for Q3 2025, versus $9.7 million for Q2 2025 and -$3.7 million for Q1 2025.